NOVN - Novan - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $22.71. This is a potential upside of $22.68 (75600%) from yesterday's end of day stock price of $0.03.

Novan's activity chart (see below) currently has 9 price targets and 13 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 3.33% with an average time for these price targets to be met of 80.4 days.

Most recent stock forecast was given by JAMES EDWARDES JONES from RBC on 01-Jun-2023. First documented stock forecast 12-Apr-2017.

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

2 years 1 months 16 days ago
(01-Jun-2023)

0/1 (0%)

$9.42 (365.12%)

Buy

$24

2 years 11 months 1 days ago
(16-Aug-2022)

1/6 (16.67%)

$15.85 (194.48%)

402

Buy

$30

2 years 11 months 28 days ago
(19-Jul-2022)

0/1 (0%)

$20.19 (205.81%)

Buy

$40

$39.97 (133233.33%)

$30

4 years 1 months 6 days ago
(11-Jun-2021)

0/2 (0%)

$20.86 (146.54%)

Buy

$110

$109.97 (366566.66%)

8 years 3 months 5 days ago
(12-Apr-2017)

0/1 (0%)

$47.1 (74.88%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NOVN (Novan) average time for price targets to be met?

On average it took 80.4 days on average for the stock forecasts to be realized with a an average price target met ratio 3.33

Which analyst has the current highest performing score on NOVN (Novan) with a proven track record?

OREN LIVNAT

Which analyst has the current lower performing score on NOVN (Novan) with a proven track record?

JAMES EDWARDES JONES

Which analyst has the most public recommendations on NOVN (Novan)?

Oren Livnat works at HC WAINWRIGHT and has 6 price targets and 4 ratings on NOVN

Which analyst is the currently most bullish on NOVN (Novan)?

David Amsellem with highest potential upside - $109.97

Which analyst is the currently most reserved on NOVN (Novan)?

Oren Livnat with lowest potential downside - -$0

Novan in the News

Novartis receives Swiss approval for first malaria drug for babies

Investing.com — Novartis (SIX:NOVN) received approval in Switzerland for Coartem Baby, the first drug specifically designed to treat malaria in babies and young children. The pharmaceutical company announced on Tuesday that eight African countries that participated in the assessment are expected to quickly approve the treatment, which is also known as Riamet Baby in some...

Novartis gets approval for first malaria drug for babies and children

ZURICH (Reuters) -Novartis on Tuesday said it had received approval in Switzerland for Coartem, which it said was the first drug to treat malaria in babies and young children. Eight African countries who participated in the assessment are now expected to issue quick approvals for the treatment, which is also known as Riamet Baby in...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?